down arrow

Aclaris Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00461U1051
USD
2.92
-0.09 (-2.99%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Kiniksa Pharmaceuticals Ltd.
Tarsus Pharmaceuticals, Inc.
Harrow, Inc.
Repare Therapeutics, Inc.
Phathom Pharmaceuticals, Inc.
Evolus, Inc.
Aclaris Therapeutics, Inc.
GH Research Plc
Savara, Inc.
Olema Pharmaceuticals, Inc.
Rapt Therapeutics, Inc.
Why is Aclaris Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate 2.04% of over the last 5 years
2
With a fall in Net Sales of -60.02%, the company declared Very Negative results in Jun 25
  • NET SALES(Q) At USD 1.78 MM has Fallen at -60.02%
  • ROCE(HY) Lowest at -101.41%
  • PRE-TAX PROFIT(Q) At USD -13.93 MM has Fallen at -29.64%
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -31.58%, its profits have risen by 46.6%
4
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -31.58% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aclaris Therapeutics, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Aclaris Therapeutics, Inc.
-23.36%
2.28
69.18%
S&P 500
12.66%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
24.87%
EBIT Growth (5y)
2.04%
EBIT to Interest (avg)
-71.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.17
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.15
EV to EBIT
-1.13
EV to EBITDA
-1.14
EV to Capital Employed
1.55
EV to Sales
3.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-137.21%
ROE (Latest)
-29.83%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -9.99 MM

NET PROFIT(HY)

Higher at USD -28.51 MM

-19What is not working for the Company
NET SALES(Q)

At USD 1.78 MM has Fallen at -60.02%

ROCE(HY)

Lowest at -101.41%

PRE-TAX PROFIT(Q)

At USD -13.93 MM has Fallen at -29.64%

RAW MATERIAL COST(Y)

Grown by 117.04% (YoY

NET PROFIT(Q)

At USD -13.93 MM has Fallen at -29.64%

Here's what is working for Aclaris Therapeutics, Inc.
Operating Cash Flow
Highest at USD -9.99 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Here's what is not working for Aclaris Therapeutics, Inc.
Net Sales
At USD 1.78 MM has Fallen at -60.02%
over average net sales of the previous four periods of USD 4.44 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -13.93 MM has Fallen at -29.64%
over average net sales of the previous four periods of USD -10.74 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -13.93 MM has Fallen at -29.64%
over average net sales of the previous four periods of USD -10.74 MM
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Raw Material Cost
Grown by 117.04% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."